CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone

被引：0
|
作者：
Stefania Crucitta
Marzia Del Re
Federico Paolieri
Francesco Bloise
Andrea Sbrana
Enrico Sammarco
Chiara Mercinelli
Federico Cucchiara
Lorenzo Fontanelli
Luca Galli
Romano Danesi
机构：
[1] University Hospital of Pisa,Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine
[2] University of Pisa,Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
CYP17A1; Polymorphism; CRPC; Abiraterone; Pharmacogenetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：527 / 533
页数：6
相关论文
共 50 条
  • [1] CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone
    Crucitta, Stefania
    Del Re, Marzia
    Paolieri, Federico
    Bloise, Francesco
    Sbrana, Andrea
    Sammarco, Enrico
    Mercinelli, Chiara
    Cucchiara, Federico
    Fontanelli, Lorenzo
    Galli, Luca
    Danesi, Romano
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (04) : 527 - 533
  • [2] CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone
    Salvi, Samanta
    Casadio, Valentina
    Burgio, Salvatore Luca
    Conteduca, Vincenza
    Rossi, Lorena
    Menna, Cecilia
    Carretta, Elisa
    Costantini, Matteo
    Zoli, Wainer
    De Giorgi, Ugo
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2016, 31 (03): : E264 - E269
  • [3] Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer
    Binder, Moritz
    Zhang, Ben Y.
    Hillman, David W.
    Kohli, Rhea
    Kohli, Tanvi
    Lee, Adam
    Kohli, Manish
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (07)
  • [4] Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
    S Salvi
    V Casadio
    V Conteduca
    S L Burgio
    C Menna
    E Bianchi
    L Rossi
    E Carretta
    C Masini
    D Amadori
    D Calistri
    G Attard
    U De Giorgi
    British Journal of Cancer, 2015, 112 : 1717 - 1724
  • [5] Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
    Salvi, S.
    Casadio, V.
    Conteduca, V.
    Burgio, S. L.
    Menna, C.
    Bianchi, E.
    Rossi, L.
    Carretta, E.
    Masini, C.
    Amadori, D.
    Calistri, D.
    Attard, G.
    De Giorgi, U.
    BRITISH JOURNAL OF CANCER, 2015, 112 (10) : 1717 - 1724
  • [6] Association of CYP17A1 single nucleotide polymorphism (SNP) with response to abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).
    Zhang, Ben Miming
    Binder, Moritz
    Costello, Brian Addis
    Quevedo, Fernando
    Kohli, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone
    Fan, Liancheng
    Chi, Chenfei
    Guo, Sanwei
    Wang, Yanqing
    Cai, Wen
    Shao, Xiaoguang
    Xu, Fan
    Pan, Jiahua
    Zhu, Yinjie
    Xun Shangguan
    Xin, Zhixiang
    Hu, Jianian
    Qian, Hongyang
    Xie, Shaowei
    Wang, Rui
    Zhou, Lixin
    Dong, Baijun
    Xue, Wei
    JOURNAL OF CANCER, 2017, 8 (17): : 3448 - 3455
  • [8] Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
    Mostaghel, Elahe A.
    Marck, Brett T.
    Plymate, Stephen R.
    Vessella, Robert L.
    Balk, Stephen
    Matsumoto, Alvin M.
    Nelson, Peter S.
    Montgomery, R. Bruce
    CLINICAL CANCER RESEARCH, 2011, 17 (18) : 5913 - 5925
  • [9] CYP17A1 T-34C polymorphism is not associated with endometrial cancer risk
    Yang, Xueying
    Feng, Aihua
    Liu, Fengying
    Li, Qun
    Zhang, Jing
    Yang, Chuanhua
    An, Yujun
    TUMOR BIOLOGY, 2013, 34 (05) : 2583 - 2587
  • [10] Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate
    Giacinti, Silvana
    Carlini, Paolo
    Roberto, Michela
    Bassanelli, Maria
    Strigari, Lidia
    Pavese, Francesco
    Aschelter, Anna M.
    Felici, Alessandra
    Valeriani, Maurizio
    Cognetti, Francesco
    Marchetti, Paolo
    ANTI-CANCER DRUGS, 2017, 28 (01) : 110 - 115
12345